SCHEMBL16808917

SCHEMBL16808917

Cc1cccc(OCc2cccc(F)c2)c1

nearest known ligand 0.71

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAOB P27338 18/20 0.71
MAOA P21397 3/20 0.61
NR4A2 P43354 1/20 0.60
MRGPRX4 Q96LA9 1/20 0.56
ACHE P22303 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16808963 0.93 MAOB (0.69) MAOBMAOANR4A2MRGPRX4
SCHEMBL1547975 0.88 MAOB (0.74) MAOBMAOAACHE
SCHEMBL15344203 0.88 MAOB (0.80) MAOBMAOAACHE
SCHEMBL12879357 0.85 MAOB (0.71) MAOBMAOANR4A2
SCHEMBL10136590 0.85 MAOB (0.71) MAOBMAOANR4A2ACHE
SCHEMBL16710557 0.83 MAOB (0.77) MAOBMAOANR4A2MRGPRX4
SCHEMBL20098914 0.83 MAOB (0.71) MAOBMAOANR4A2MRGPRX4
SCHEMBL15474222 0.83 MAOB (0.67) MAOBMAOANR4A2ACHE
SCHEMBL11959694 0.82 MAOB (0.72) MAOBMAOANR4A2
SCHEMBL685837 0.82 MAOB (0.68) MAOBMAOANR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190099747-A1 NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER UNIV CALIFORNIA (US) 2019-04-04 US disclosed
US-20170341069-A1 NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER UNIV CALIFORNIA (US) 2017-11-30 US disclosed
US-20160339418-A1 NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER LIPSHUTZ BRUCE H (US) 2016-11-24 US disclosed
WO-2015087094-A1 NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SEMMELWEIS EGYETEM (HU) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190099747-A1 NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER SOD1, MPO, TFRC MAOB 753/4885MAOA 535/4885NR4A2 3008/4885
US-20160339418-A1 NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER SOD1, MPO, TFRC MAOB 583/4885MAOA 375/4885NR4A2 3503/4885
US-20170341069-A1 NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER SOD1, MPO, TFRC MAOB 753/4885MAOA 535/4885NR4A2 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.